Ascendis Pharma ADR (ASND)

$223.59 -2.51 (-1.11%)
Market Cap 14.01B
Revenue (ttm) 393.50M
Net Income (ttm) -409.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 66.28
Profit Margin -103.97%
Debt to Equity Ratio -4.67
Volume 302,300
Avg Vol 667,402
Day's Range N/A - N/A
Shares Out 61.98M
Stochastic %K 43%
Beta 0.46
Analysts Strong Sell
Price Target $269.12

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candid...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 22 22 44
Address:
Tuborg Boulevard 12, Hellerup, Denmark
erevnon
erevnon Jan. 30 at 2:38 PM
B of A Securities maintains Ascendis Pharma $ASND at Buy and raises the price target from $246 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 2:09 AM
$ASND Share Price: $222.21 Contract Selected: Jun 18, 2026 $220 Calls Buy Zone: $21.34 – $26.36 Target Zone: $38.59 – $47.17 Potential Upside: 71% ROI Time to Expiration: 140 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
tymtested
tymtested Jan. 28 at 8:36 PM
$ASND guess there's no takeover
0 · Reply
WAJeff
WAJeff Jan. 28 at 4:35 PM
Added $GH 110.51 $ASND 227.51
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 24 at 1:32 PM
$ASND RSI: 65.00, MACD: 4.2454 Vol: 7.32, MA20: 213.72, MA50: 209.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JFais
JFais Jan. 22 at 7:38 PM
$ASND- rumor European pharma takeover (would be ideal, no political/regulatory drama Would also free up $18B+ of cash for pharma to reinvest in biotech ecosystem $XBI
0 · Reply
notreload_ai
notreload_ai Jan. 22 at 5:50 PM
$ASND shares rose after new takeover speculation involving European pharmaceutical companies, according to market chatter. https://notreload.xyz/ascendis-pharma-stock-jumps-on-takeover-rumors/
0 · Reply
Pika_Capital
Pika_Capital Jan. 22 at 4:52 PM
$ASND what's cooking 👀👀
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 19 at 8:08 PM
$ASND Massive volume spike on Jan 13 with 1.36M shares traded. Price dropped from $220.42 to $119.49 within a short period. Current price at $205.83 with an average volume of 516,403. Waiting for a lower H% to consider buying in.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 19 at 2:53 PM
$ASND Share Price: $205.76 Contract Selected: Jun 18, 2026 $210 Calls Buy Zone: $19.97 – $24.68 Target Zone: $36.00 – $44.00 Potential Upside: 70% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on ASND
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:46 PM EST - 21 days ago

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 6:01 PM EST - 24 days ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Jan 8, 2026, 10:34 PM EST - 25 days ago

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

Jan 8, 2026, 4:01 PM EST - 25 days ago

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Here's My Prediction For Who Could Acquire Ascendis Pharma

Dec 15, 2025, 3:18 AM EST - 7 weeks ago

Here's My Prediction For Who Could Acquire Ascendis Pharma

Eight stock picks to play one of the healthiest corners of the market

Dec 11, 2025, 10:37 AM EST - 7 weeks ago

Eight stock picks to play one of the healthiest corners of the market

ALNY INSM MASI NTRA PODD UNH WGS

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

Dec 11, 2025, 3:45 AM EST - 7 weeks ago

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

ABT AI AXON AZO CPRT DXCM HOOD

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

Dec 8, 2025, 1:54 PM EST - 2 months ago

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

IYC MPWR GPIQ

Ascendis: Q3 Results Validate The TransCon Platform

Dec 5, 2025, 4:48 AM EST - 2 months ago

Ascendis: Q3 Results Validate The TransCon Platform

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026

Nov 28, 2025, 10:13 AM EST - 2 months ago

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

Nov 25, 2025, 6:21 PM EST - 2 months ago

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

Nov 25, 2025, 6:15 PM EST - 2 months ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

Nov 17, 2025, 4:01 PM EST - 2 months ago

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 9:01 PM EST - 2 months ago

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:01 PM EST - 2 months ago

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Nov 12, 2025, 7:14 AM EST - 2 months ago

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Nov 7, 2025, 8:30 AM EST - 3 months ago

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

Nov 5, 2025, 4:01 PM EST - 3 months ago

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

Nov 3, 2025, 4:01 PM EST - 3 months ago

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 3 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

Oct 8, 2025, 4:01 PM EDT - 4 months ago

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

Sep 2, 2025, 4:01 PM EDT - 5 months ago

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 4:01 PM EDT - 5 months ago

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:46 AM EDT - 6 months ago

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 31, 2025, 4:01 PM EDT - 6 months ago

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Jul 28, 2025, 7:00 AM EDT - 6 months ago

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Jul 14, 2025, 4:01 PM EDT - 7 months ago

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

Jul 7, 2025, 4:01 PM EDT - 7 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Jun 9, 2025, 7:00 AM EDT - 8 months ago

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

FDA Accepts TransCon® CNP NDA for Priority Review

Jun 2, 2025, 8:00 AM EDT - 8 months ago

FDA Accepts TransCon® CNP NDA for Priority Review

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

May 20, 2025, 6:00 AM EDT - 9 months ago

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 13, 2025, 4:01 PM EDT - 9 months ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 12, 2025, 4:45 PM EDT - 9 months ago

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 5, 2025, 8:30 AM EDT - 9 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:35 PM EDT - 9 months ago

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 9 months ago

Ascendis Pharma Reports First Quarter 2025 Financial Results

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Apr 24, 2025, 4:01 PM EDT - 10 months ago

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Apr 14, 2025, 4:38 PM EDT - 10 months ago

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Mar 31, 2025, 4:01 PM EDT - 11 months ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:01 PM EST - 1 year ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Feb 13, 2025, 2:40 PM EST - 1 year ago

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 11:03 PM EST - 1 year ago

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Feb 12, 2025, 4:05 PM EST - 1 year ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 4:01 PM EST - 1 year ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Feb 5, 2025, 4:01 PM EST - 1 year ago

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

Jan 29, 2025, 11:25 AM EST - 1 year ago

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

Ascendis Pharma: Danish Blockbuster Hunter

Jan 29, 2025, 12:31 AM EST - 1 year ago

Ascendis Pharma: Danish Blockbuster Hunter

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Jan 12, 2025, 5:00 PM EST - 1 year ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

erevnon
erevnon Jan. 30 at 2:38 PM
B of A Securities maintains Ascendis Pharma $ASND at Buy and raises the price target from $246 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 2:09 AM
$ASND Share Price: $222.21 Contract Selected: Jun 18, 2026 $220 Calls Buy Zone: $21.34 – $26.36 Target Zone: $38.59 – $47.17 Potential Upside: 71% ROI Time to Expiration: 140 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
tymtested
tymtested Jan. 28 at 8:36 PM
$ASND guess there's no takeover
0 · Reply
WAJeff
WAJeff Jan. 28 at 4:35 PM
Added $GH 110.51 $ASND 227.51
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 24 at 1:32 PM
$ASND RSI: 65.00, MACD: 4.2454 Vol: 7.32, MA20: 213.72, MA50: 209.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JFais
JFais Jan. 22 at 7:38 PM
$ASND- rumor European pharma takeover (would be ideal, no political/regulatory drama Would also free up $18B+ of cash for pharma to reinvest in biotech ecosystem $XBI
0 · Reply
notreload_ai
notreload_ai Jan. 22 at 5:50 PM
$ASND shares rose after new takeover speculation involving European pharmaceutical companies, according to market chatter. https://notreload.xyz/ascendis-pharma-stock-jumps-on-takeover-rumors/
0 · Reply
Pika_Capital
Pika_Capital Jan. 22 at 4:52 PM
$ASND what's cooking 👀👀
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 19 at 8:08 PM
$ASND Massive volume spike on Jan 13 with 1.36M shares traded. Price dropped from $220.42 to $119.49 within a short period. Current price at $205.83 with an average volume of 516,403. Waiting for a lower H% to consider buying in.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 19 at 2:53 PM
$ASND Share Price: $205.76 Contract Selected: Jun 18, 2026 $210 Calls Buy Zone: $19.97 – $24.68 Target Zone: $36.00 – $44.00 Potential Upside: 70% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Mirko1977
Mirko1977 Jan. 16 at 5:26 PM
$ASND
0 · Reply
Merlintrader
Merlintrader Jan. 16 at 3:15 PM
$ASND https://www.merlintrader.com/asnd-ascendis-pharma/
0 · Reply
Hognose
Hognose Jan. 14 at 7:06 PM
$VKTX $ASND $RYTM $ABVX $PCVX my potential buyout portfolio.
0 · Reply
WAJeff
WAJeff Jan. 13 at 5:49 PM
$ASND 8/28 194.92s sold 218. Like it but it didn't do too much.
0 · Reply
sasanalyst
sasanalyst Jan. 13 at 4:47 PM
$ASND The Annual height velocity for Achondroplasia is good. Look at Feb Pdufa play.
0 · Reply
CrispDry
CrispDry Jan. 13 at 4:42 PM
$ASND added 5% portfolio weight under $200. Amazing dip
0 · Reply
Pika_Capital
Pika_Capital Jan. 13 at 4:16 PM
$ASND so what MORONS sold yesterday in $190S 😂😂 🤡
0 · Reply
SenefAS
SenefAS Jan. 12 at 5:38 PM
Good entry point today for Ascendis - Upgraded by Wells for overweight 332$ - Disappointed by the news of Abivax $ASND $ABVX #biotech
0 · Reply
CrispDry
CrispDry Jan. 12 at 4:24 PM
$ASND happy to add in 190s today
0 · Reply
Hognose
Hognose Jan. 12 at 3:59 PM
$ASND buy
0 · Reply
Pika_Capital
Pika_Capital Jan. 12 at 2:36 PM
$ASND clowns selling after Yorvipath delivered stellar numbers
1 · Reply
judgeyoung2
judgeyoung2 Jan. 7 at 10:41 PM
$ASND $GPCR when buyouts
0 · Reply